Last reviewed · How we verify
Liposomal doxorubicin, Paclitaxel or Topotecan
Liposomal doxorubicin, Paclitaxel or Topotecan is a Chemotherapy combination (anthracycline, taxane, camptothecin analog) Small molecule drug developed by Sichuan Baili Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Advanced or metastatic solid tumors (specific indication under Phase 3 evaluation by Sichuan Baili).
This is a combination of three distinct chemotherapy agents—liposomal doxorubicin (intercalates DNA), paclitaxel (stabilizes microtubules), and topotecan (inhibits topoisomerase I)—each with different mechanisms to kill cancer cells.
This is a combination of three distinct chemotherapy agents—liposomal doxorubicin (intercalates DNA), paclitaxel (stabilizes microtubules), and topotecan (inhibits topoisomerase I)—each with different mechanisms to kill cancer cells. Used for Advanced or metastatic solid tumors (specific indication under Phase 3 evaluation by Sichuan Baili).
At a glance
| Generic name | Liposomal doxorubicin, Paclitaxel or Topotecan |
|---|---|
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Drug class | Chemotherapy combination (anthracycline, taxane, camptothecin analog) |
| Target | DNA (doxorubicin), β-tubulin (paclitaxel), Topoisomerase I (topotecan) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Liposomal doxorubicin intercalates into DNA and generates reactive oxygen species, disrupting replication and transcription. Paclitaxel binds β-tubulin and prevents microtubule depolymerization, halting mitosis. Topotecan inhibits topoisomerase I, preventing DNA unwinding and causing strand breaks. The combination leverages synergistic cytotoxic effects across multiple pathways.
Approved indications
- Advanced or metastatic solid tumors (specific indication under Phase 3 evaluation by Sichuan Baili)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea/vomiting
- Mucositis
- Peripheral neuropathy (paclitaxel-related)
- Cardiotoxicity (doxorubicin-related)
- Diarrhea
Key clinical trials
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (PHASE3)
- Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (PHASE2, PHASE3)
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (PHASE2)
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (PHASE3)
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (PHASE2, PHASE3)
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (PHASE2, PHASE3)
- HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal doxorubicin, Paclitaxel or Topotecan CI brief — competitive landscape report
- Liposomal doxorubicin, Paclitaxel or Topotecan updates RSS · CI watch RSS
- Sichuan Baili Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Liposomal doxorubicin, Paclitaxel or Topotecan
What is Liposomal doxorubicin, Paclitaxel or Topotecan?
How does Liposomal doxorubicin, Paclitaxel or Topotecan work?
What is Liposomal doxorubicin, Paclitaxel or Topotecan used for?
Who makes Liposomal doxorubicin, Paclitaxel or Topotecan?
What drug class is Liposomal doxorubicin, Paclitaxel or Topotecan in?
What development phase is Liposomal doxorubicin, Paclitaxel or Topotecan in?
What are the side effects of Liposomal doxorubicin, Paclitaxel or Topotecan?
What does Liposomal doxorubicin, Paclitaxel or Topotecan target?
Related
- Drug class: All Chemotherapy combination (anthracycline, taxane, camptothecin analog) drugs
- Target: All drugs targeting DNA (doxorubicin), β-tubulin (paclitaxel), Topoisomerase I (topotecan)
- Manufacturer: Sichuan Baili Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic solid tumors (specific indication under Phase 3 evaluation by Sichuan Baili)
- Compare: Liposomal doxorubicin, Paclitaxel or Topotecan vs similar drugs
- Pricing: Liposomal doxorubicin, Paclitaxel or Topotecan cost, discount & access